Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224

The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis

D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024

Measurement of Delusional Ideation in the Normal Population: Introducing the PDI (Peters et al. Delusions Inventory)

Peters, E. R., Joseph, S. A., & Garety, P. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033401 · Cited by 771

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 415

Short scales for measuring schizotypy.

Mason, O., Linney, Y., & Claridge, G. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.06.020 · Cited by 355

Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man

Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 150

Dorsolateral Prefrontal Cortex N-Acetylaspartate/Total Creatine (NAA/tCr) Loss in Male Recreational Cannabis Users

Hermann, D., Sartorius, A., Welzel, H., Walter, S., Skopp, G., Ende, G., & Mann, K. F. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.027 · Cited by 135

GC-MS Analysis of the Total Δ9-THC Content of Both Drug- and Fiber-Type Cannabis Seeds

Ross, S. A., Mehmedic, Z., Murphy, T. P., & ElSohly, M. A. (2000) · Journal of Analytical Toxicology · doi:10.1093/jat/24.8.715 · Cited by 133

The Incidence of Schizotypy among Cannabis and Alcohol Users

Nunn, J. A., Rizza, F., & PETERS, E. R. (2001) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200111000-00002 · Cited by 122

Criminology, deviant behaviour, and mental disorder

West, D. J. (1974) · Psychological Medicine · doi:10.1017/s0033291700040253 · Cited by 84

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000

Cannabidiol as a Potential Treatment for Anxiety Disorders

Blessing, E., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 752

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study

Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00117-5 · Cited by 588

High-potency cannabis and the risk of psychosis

Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567

Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 552

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

Englund, A., Morrison, P. D., Nottage, J. F., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 479

Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations

Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Foll, B. L., Hall, W., Rehm, J. T., & Room, R. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.303818 · Cited by 474

Association Between Cannabis and Psychosis: Epidemiologic Evidence

Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379

Keep off the grass? Cannabis, cognition and addiction

Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 389

Spice drugs as a new trend: Mode of action, identification and legislation

Vardakou, I., Pistos, C. M., & Spiliopoulou, C. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2010.06.002 · Cited by 341

Modelling suicide and unemployment: a longitudinal analysis covering 63 countries, 2000–11

Nordt, C., Warnke, I., Seifritz, E., & Kawohl, W. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00118-7 · Cited by 322

Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis

Murray, R. M., Quigley, H., Quattrone, D., Englund, A., & Forti, M. D. (2016) · World Psychiatry · doi:10.1002/wps.20341 · Cited by 332

Examining the profile of high-potency cannabis and its association with severity of cannabis dependence

Freeman, T. P., & WINSTOCK, A. R. (2015) · Psychological Medicine · doi:10.1017/s0033291715001178 · Cited by 326

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study

Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305

Synthetic cannabinoid JWH-018 and psychosis: An explorative study

Every‐Palmer, S. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.01.012 · Cited by 300

Spicing things up: synthetic cannabinoids

Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 314

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Martín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298

A systematic review of the antipsychotic properties of cannabidiol in humans

Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261

The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample

Yücel, M., Bora, E., Lubman, D. I., Solowij, N., Brewer, W. J., Cotton, S., Conus, P., Takagi, M., Fornito, A., Wood, S. J., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq079 · Cited by 255

The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects

van Amsterdam, J., Brunt, T., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565142 · Cited by 244

Medical cannabis and mental health: A guided systematic review

Walsh, Z., González, R., Crosby, K., Thiessen, M. S., Carroll, C., & Bonn‐Miller, M. O. (2016) · Clinical Psychology Review · doi:10.1016/j.cpr.2016.10.002 · Cited by 260

Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

Niesink, R. J. M., & van Laar, M. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00130 · Cited by 253

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol

Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 250

Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models

Malone, D. T., Hill, M. N., & Rubino, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00721.x · Cited by 237

Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis

Hindley, G., Beck, K., Borgan, F., Ginestet, C. E., McCutcheon, R. A., Kleinloog, D., Ganesh, S., Radhakrishnan, R., D’Souza, D. C., & Howes, O. D. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30074-2 · Cited by 229

Cannabis with high cannabidiol content is associated with fewer psychotic experiences

Schubart, C. D., Sommer, I. E., van Gastel, W. A., Goetgebuer, R., Kahn, R. S., & Boks, M. P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.017 · Cited by 238

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation

Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222

How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review

Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.036 · Cited by 232

‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration

Freeman, T. P., & Lorenzetti, V. (2019) · Addiction · doi:10.1111/add.14842 · Cited by 222

Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders

Scuderi, C., Filippis, D. D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2008) · Phytotherapy Research · doi:10.1002/ptr.2625 · Cited by 217

The Role of cannabinoids in neuroanatomic alterations in cannabis users.

Lorenzetti, V., Solowij, N., & Yücel, M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.013 · Cited by 208

Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis

Wolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208

Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats

Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L. E., Huang, X.-F., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2342-0 · Cited by 206

A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice

Long, L. E., Chesworth, R., Huang, X., McGregor, I. S., Arnold, J. C., & Karl, T. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990605 · Cited by 211

Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing

Bhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203

Cannabis-associated psychosis: Neural substrate and clinical impact

Murray, R. M., Englund, A., Abi‐Dargham, A., Lewis, D. A., Forti, M. D., Davies, C., Sherif, M. A., McGuire, P. K., & D’Souza, D. C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.018 · Cited by 210

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being

Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001322 · Cited by 195

“Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report

Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., Impagnatiello, M., Pascolo‐Fabrici, E., & Bonavigo, T. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2312 · Cited by 191

Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice

Ortega-Álvaro, A., Aracil-Fernández, A., García‐Gutiérrez, M. S., Navarrete, F., & Manzanares, J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.34 · Cited by 190

A Characterization of Synthetic Cannabinoid Exposures Reported to the National Poison Data System in 2010

Hoyte, C. O., Jacob, J. E., Monte, A. A., Aljumaan, M. A., Bronstein, A. C., & Heard, K. J. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.03.007 · Cited by 185

Brain Cannabinoid CB2 Receptor in Schizophrenia

Ishiguro, H., Horiuchi, Y., Ishikawa, M., Koga, M., Imai, K., Suzuki, Y., Morikawa, M., Inada, T., Watanabe, Y., Takahashi, M., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.024 · Cited by 188

CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity

Onaivi, E. S., Ishiguro, H., Gu, S., & Liu, Q. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111400652 · Cited by 190

The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes

Müller, H., Sperling, W., Köhrmann, M., Huttner, H. B., Kornhuber, J., & Maler, J.-M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.001 · Cited by 183

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users

Hindocha, C., Freeman, T. P., Schäfer, G., Gardener, C., Das, R., Morgan, C. J. A., & Curran, H. V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.014 · Cited by 192

Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile

Swift, W., Wong, A. C. H., Li, K. M., Arnold, J. C., & McGregor, I. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070052 · Cited by 185

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

Arkell, T. R., Lintzeris, N., Kevin, R. C., Ramaekers, J. G., Vandrey, R. G., Irwin, C. G., Haber, P., & McGregor, I. S. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05246-8 · Cited by 182

The Endocannabinoid System, Cannabinoids, and Pain

Fine, P. G., & Rosenfeld, M. J. (2013) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10129 · Cited by 213

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

Koethe, D., Giuffrida, A., Schreiber, D., Hellmich, M., Schultze‐Lutter, F., Ruhrmann, S., Klosterkötter, J., Piomelli, D., & Leweke, F. M. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.053843 · Cited by 178

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose

Seeman, P. M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.195 · Cited by 189

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects

Solowij, N., Broyd, S. J., Greenwood, L., van Hell, H., Martelozzo, D., Rueb, K., Todd, J., Liu, Z., Galettis, P., Martin, J. H., et al. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00978-2 · Cited by 176

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 180

The association between cannabis use and mood disorders: A longitudinal study

Feingold, D., Weiser, M., Rehm, J. T., & Lev‐Ran, S. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.006 · Cited by 166

Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol

Demirakca, T., Sartorius, A., Ende, G., Meyer, N., Welzel, H., Skopp, G., Mann, K., & Hermann, D. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.09.020 · Cited by 162

Cannabidiol reduces ethanol consumption, motivation and relapse in mice

Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 158

Can we make cannabis safer?

Englund, A., Freeman, T. P., Murray, R. M., & McGuire, P. K. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30075-5 · Cited by 156

A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia

Osborne, A. L., Solowij, N., & Weston–Green, K. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.012 · Cited by 154

Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial

Bhattacharyya, S., Wilson, R., Appiah-Kusi, E., O'Neill, A., Brammer, M., Perez, J., Murray, R., Allen, P., Bossong, M., & McGuire, P. (2018) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2018.2309 · Cited by 134

Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems

Moltke, J., & Hindocha, C. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00061-5 · Cited by 162

Just say ‘know’: how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?

Freeman, T. P., Morgan, C. J. A., Hindocha, C., Schäfer, G., Das, R., & Curran, H. V. (2014) · Addiction · doi:10.1111/add.12634 · Cited by 140

Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents

Fasinu, P. S., Phillips, S., ElSohly, M. A., & Walker, L. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1780 · Cited by 140

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function

Morgan, C. J. A., Freeman, T. P., Hindocha, C., Schäfer, G., Gardner, C., & Curran, H. V. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0191-x · Cited by 140

Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects

Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 139

Cannabis Use and the Risk for Psychosis and Affective Disorders

Sideli, L., Quigley, H., Cascia, C. L., & Murray, R. M. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1674991 · Cited by 146

The Assessment of Schizotypy and Its Clinical Relevance

Mason, O. J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu194 · Cited by 141

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial

Solowij, N., Broyd, S. J., Beale, C., Prick, J.-A., Greenwood, L., van Hell, H., Suo, C., Galettis, P., Pai, N. B., Fu, S., et al. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0043 · Cited by 130

Impact of Cannabis Use on the Development of Psychotic Disorders

Wilkinson, S. T., Radhakrishnan, R., & D’Souza, D. C. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0018-7 · Cited by 139

Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues

Russo, E. B. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00309 · Cited by 128

Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia

Müller‐Vahl, K., & Emrich, H. M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.7.1037 · Cited by 125

Chronic Adolescent Δ 9 -Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment

Murphy, M. N., Mills, S., Winstone, J., Leishman, E., Wager‐Miller, J., Bradshaw, H. B., & Mackie, K. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0034 · Cited by 131

Psychosis reactivity to cannabis use in daily life: an experience sampling study

Henquet, C., van Os, J., Kuepper, R., Delespaul, P., Smits, M., Campo, J. Á., & Myin‐Germeys, I. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.072249 · Cited by 121

Therapeutic potential of cannabinoid medicines

Robson, P. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1529 · Cited by 126

Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment

Urigüen, L., García-Fuster, M. J., Callado, L. F., Morentín, B., Harpe, R. L., Casadó, V., Lluís, C., Franco, R., Garcı́a-Sevilla, J. A., & Meana, J. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1608-2 · Cited by 115

Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience

Bhattacharyya, S., Falkenberg, I., Martín‐Santos, R., Atakan, Z., Crippa, J. A. S., Giampietro, V., Brammer, M. J., & McGuire, P. K. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.258 · Cited by 114

The effect of cannabis use on memory function: an update

Bhattacharyya, S., & Schoeler, T. (2013) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s25869 · Cited by 112

Neuropsychological Consequences of Chronic Drug Use: Relevance to Treatment Approaches

Cadet, J. L., & Bisagno, V. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00189 · Cited by 110

Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview

Esposito, G., Filippis, D. D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R., & Steardo, L. (2012) · Phytotherapy Research · doi:10.1002/ptr.4781 · Cited by 105

The association between cannabis use and anxiety disorders: Results from a population-based representative sample

Feingold, D., Weiser, M., Rehm, J. T., & Lev‐Ran, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.037 · Cited by 109

Cannabidiol as a potential treatment for psychosis

Schubart, C. D., Sommer, I. E., Fusar‐Poli, P., de Witte, L. D., Kahn, R. S., & Boks, M. P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.002 · Cited by 105

Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model

Xu, C., Chang, T., Du, Y., Yu, C., Tan, X. L., & Li, X. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2019.103202 · Cited by 100

Cannabinoids and Psychosis

D’Souza, D. C. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78010-2 · Cited by 98

The Association between Regular Cannabis Exposure and Alterations of Human Brain Morphology: An Updated Review of the Literature

Lorenzetti, V., Solowij, N., Fornito, A., Lubman, D. I., & Yücel, M. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990435 · Cited by 99

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios

Englund, A., Oliver, D., Chesney, E., Chester, L. A., Wilson, J., Sovi, S., Micheli, A. D., Hodsoll, J. P., Fusar‐Poli, P., Strang, J., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01478-z · Cited by 96

Potency trends of Δ9‐tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15

Niesink, R. J. M., Rigter, S., Koeter, M. W. J., & Brunt, T. M. (2015) · Addiction · doi:10.1111/add.13082 · Cited by 94

Cannabinoid derivatives and the pharmacological management of pain

Lessa, M. A., Cavalcanti, I. L., & Figueiredo, N. V. (2016) · Revista Dor · doi:10.5935/1806-0013.20160012 · Cited by 104

Therapeutic Potential of Cannabinoids in Psychosis

Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.018 · Cited by 96

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity

Wall, M. B., Pope, R. A., Freeman, T. P., Kowalczyk, O. S., Demetriou, L., Mokrysz, C., Hindocha, C., Lawn, W., Bloomfield, M., Freeman, A. M., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119841568 · Cited by 92

Cannabinoids and psychosis

Sewell, R. A., Ranganathan, M., & D’Souza, D. C. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782802 · Cited by 87

Associations between butane hash oil use and cannabis-related problems

Meier, M. H. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.015 · Cited by 91

Cannabis and development of dual diagnoses: A literature review

Hanna, R. C., Perez, J. M., & Ghose, S. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2016.1213273 · Cited by 93

Uso terapêutico dos canabinoides em psiquiatria

Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 93

Heterogeneity in the composition of marijuana seized in California

Burgdorf, J. R., Kilmer, B., & Pacula, R. L. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.11.031 · Cited by 81

Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population

Gage, S. H., Zammit, S., & Hickman, M. (2013) · F1000 Medicine Reports · doi:10.3410/m5-2 · Cited by 78

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users

Beale, C., Broyd, S. J., Chye, Y., Suo, C., Schira, M. M., Galettis, P., Martin, J. H., Yücel, M., & Solowij, N. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0047 · Cited by 82

Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.626010 · Cited by 81

Neural correlates of interactions between cannabidiol and Δ 9 ‐tetrahydrocannabinol in mice: implications for medical cannabis

Todd, S. M., & Arnold, J. C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13333 · Cited by 72

Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis

Mason, O. J., Morgan, C. J. A., Dhiman, S. K., Patel, A., Parti, N., Patel, A., & Curran, H. V. (2008) · Psychological Medicine · doi:10.1017/s0033291708004741 · Cited by 71

Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia

Ringen, P. A., Vaskinn, A., Sundet, K. S., Engh, J. A., Jónsdóttir, H., Simonsen, C., Friis, S., Opjordsmoen, S., Melle, I. S., & Andreassen, O. A. (2009) · Psychological Medicine · doi:10.1017/s0033291709991620 · Cited by 68

Hair concentrations of Δ-9-tetrahydrocannabinol and cannabidiol in cannabis consumers psychiatric patients

Barguil, Y., Chiaradia, L., Southwell, G., & Charlot, J.-Y. (2022) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2022.07.002 · Cited by 1

Hair concentrations of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in cannabis consumers psychiatric patients (Preprint)Preprint

Barguil, Y., Chiaradia, L., Southwell, G., & Charlot, J.-Y. (2022) · doi:10.2196/preprints.39958

Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen

Johnson, K., Weldon, A. J., & Burmeister, M. A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386263 · Cited by 14

Efficacy of Cannabidiol for Delta-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Bartoli, F., Riboldi, I., Bachi, B., Calabrese, A., Moretti, F., Crocamo, C., & Carrà, G. (2021) · UCL Discovery (University College London)

Cannabis with high cannabidiol content is associated with fewer psychotic experiences

Schubart, C. D., Sommer, I. E., van Gastel, W. A., Goetgebuer, R., Kahn, R. S., & Boks, M. P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.017 · Cited by 238